GlassScriptPhysician profile
Daniel R Olney
NPI 1932155900
$1,016.48
in general payments reported to CMS, 2019-2025
15 companies · $275 in 2025
The $275 reported for 2025 was less than what a typical Otolaryngology/Facial Plastic Surgery provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $33.09 · 2021: $78.67 · 2022: $120 · 2023: $80.47 · 2024: $305 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $661.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $390.92 | 2024-2025 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Acclarent, INC | $144.47 | 2021-2023 | Trudi Nav Cable, Acclarent Aera |
| Genzyme Corporation | $102.67 | 2024-2025 | |
| Stryker Corporation | $93.46 | 2019-2022 | |
| Itamar Medical INC | $42.22 | 2022 | |
| Intersect Ent, INC. | $38.63 | 2019-2020 | |
| Karl Storz Endoscopy-America | $32.79 | 2019 | |
| Allergan, INC. | $29.35 | 2019-2020 | |
| Revance Therapeutics, INC. | $24.87 | 2024 | Daxxify |
| Medtronic, INC. | $24.20 | 2024 | Propel |
| Regeneron Healthcare Solutions, INC. | $22.23 | 2023 | Dupixent |
| Aerin Medical INC. | $21.18 | 2024 | |
| Resmed Corp | $18.99 | 2019 | |
| Glaxosmithkline, LLC. | $16.72 | 2025 | Nucala |
| Covidien LP | $13.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Olney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.